HK1065489A1 - Modulators of p-selectin glycoprotein ligand 1 - Google Patents

Modulators of p-selectin glycoprotein ligand 1

Info

Publication number
HK1065489A1
HK1065489A1 HK04108412.9A HK04108412A HK1065489A1 HK 1065489 A1 HK1065489 A1 HK 1065489A1 HK 04108412 A HK04108412 A HK 04108412A HK 1065489 A1 HK1065489 A1 HK 1065489A1
Authority
HK
Hong Kong
Prior art keywords
cell
modulators
selectin glycoprotein
glycoprotein ligand
induce
Prior art date
Application number
HK04108412.9A
Other languages
English (en)
Inventor
Rong-Hwa Lin
Chung-Hsiun Wu
Pei-Ling Hsu
Original Assignee
Abgenomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics Corp filed Critical Abgenomics Corp
Publication of HK1065489A1 publication Critical patent/HK1065489A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
HK04108412.9A 2001-08-03 2004-10-27 Modulators of p-selectin glycoprotein ligand 1 HK1065489A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31019601P 2001-08-03 2001-08-03
US10/051,497 US7744888B2 (en) 2001-08-03 2002-01-18 Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
PCT/US2002/007498 WO2003013603A1 (en) 2001-08-03 2002-03-13 Modulators of p-selectin glycoprotein ligand 1

Publications (1)

Publication Number Publication Date
HK1065489A1 true HK1065489A1 (en) 2005-02-25

Family

ID=26729479

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04108412.9A HK1065489A1 (en) 2001-08-03 2004-10-27 Modulators of p-selectin glycoprotein ligand 1
HK09103684.6A HK1124624A1 (en) 2001-08-03 2009-04-22 Antibody binding p-selectin glycoprotein ligand 1 (psgl-1) for use in treating allergic disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK09103684.6A HK1124624A1 (en) 2001-08-03 2009-04-22 Antibody binding p-selectin glycoprotein ligand 1 (psgl-1) for use in treating allergic disease

Country Status (20)

Country Link
US (3) US7744888B2 (zh)
EP (2) EP1411982B1 (zh)
JP (3) JP4815101B2 (zh)
KR (1) KR100850731B1 (zh)
CN (2) CN1304051C (zh)
AT (2) ATE531734T1 (zh)
AU (1) AU2002305041B2 (zh)
CA (1) CA2428822C (zh)
CY (2) CY1108701T1 (zh)
DE (1) DE60229394D1 (zh)
DK (2) DK1985634T3 (zh)
ES (2) ES2376948T3 (zh)
HK (2) HK1065489A1 (zh)
IL (4) IL160168A0 (zh)
MX (1) MXPA04001047A (zh)
NO (2) NO333456B1 (zh)
NZ (1) NZ531199A (zh)
PT (2) PT1411982E (zh)
TW (1) TWI327070B (zh)
WO (1) WO2003013603A1 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
NZ546203A (en) * 2003-09-15 2009-05-31 Abgenomics Co Modulators of P-Selectin Glycoprotein ligand 1
US7459523B2 (en) * 2003-11-12 2008-12-02 Wisconsin Alumni Research Foundation Equine P-selectin glycoprotein ligand-1 and uses thereof
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
AU2012201999C1 (en) * 2004-05-10 2016-05-12 Abgenomics Cooperatief U.A. Antibodies
NZ590478A (en) * 2004-05-11 2012-07-27 Abgenomics Cooperatief Ua Peptide motif Pro-Met-(Glu or Ser)-Ile used to identify a ligand which on binding an activated T-cell receptor induces apoptosis or cell death
WO2007033959A2 (en) * 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
JP2011524858A (ja) * 2008-05-15 2011-09-08 セレクシーズ ファーマスーティカルズ コーポレーション 抗ｐｓｇｌ−１抗体並びにその同定及び使用方法
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
JP7240808B2 (ja) * 2014-07-08 2023-03-16 サンフォード バーナム プレビーズ メディカル ディスカバリー インスティテュート Ｐｓｇｌ－１モジュレーターおよびその使用
TWI753875B (zh) 2016-01-08 2022-02-01 美商美國全心醫藥生技股份有限公司 四價抗psgl-1抗體及其用途
US20170241415A1 (en) * 2016-02-19 2017-08-24 Muzan, Inc. Sanitary check valve
KR20230132603A (ko) 2017-01-11 2023-09-15 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
CN110740749A (zh) 2017-03-14 2020-01-31 戊瑞治疗有限公司 在酸性pH下与VISTA结合的抗体
SG11202100102VA (en) 2018-07-11 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to vista at acidic ph
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
US20220221444A1 (en) * 2019-05-03 2022-07-14 The University Of Hong Kong Method for peritoneal metastatic cell detection and isolation thereof
BR112021024242A2 (pt) * 2019-06-04 2022-04-26 Verseau Therapeutics Inc Composições e métodos anti-psgl-1 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) * 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
AU694933B2 (en) * 1993-01-25 1998-08-06 Dana-Farber Cancer Institute, Inc. Chimeric L- and P-selectin by exchange of domains - uses thereof
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
JPH11510543A (ja) 1995-08-03 1999-09-14 ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ ペプチド及びセレクチン介在炎症のｏ−グリカン阻害剤
JPH09227410A (ja) 1996-02-21 1997-09-02 Sumitomo Pharmaceut Co Ltd 臓器移植拒絶反応の抑制剤
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
IL142717A0 (en) 1998-10-30 2002-03-10 Genetics Inst Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
HUP0700079A2 (en) 2000-12-29 2007-05-02 Savient Pharmaceuticals Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
NZ590478A (en) 2004-05-11 2012-07-27 Abgenomics Cooperatief Ua Peptide motif Pro-Met-(Glu or Ser)-Ile used to identify a ligand which on binding an activated T-cell receptor induces apoptosis or cell death
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
EP1985634A1 (en) 2008-10-29
AU2002305041B2 (en) 2005-11-10
HK1124624A1 (en) 2009-07-17
IL160168A0 (en) 2004-07-25
CN101045161B (zh) 2010-06-16
ATE531734T1 (de) 2011-11-15
JP2008260759A (ja) 2008-10-30
NZ531199A (en) 2004-11-26
CN1304051C (zh) 2007-03-14
ES2316569T3 (es) 2009-04-16
US7744888B2 (en) 2010-06-29
CY1112966T1 (el) 2016-04-13
US8298540B2 (en) 2012-10-30
NO333456B1 (no) 2013-06-10
ATE411045T1 (de) 2008-10-15
DE60229394D1 (en) 2008-11-27
DK1411982T3 (da) 2009-02-16
CN1473052A (zh) 2004-02-04
CN101045161A (zh) 2007-10-03
NO20040460L (no) 2004-02-24
NO20130069L (no) 2004-02-24
IL210557A0 (en) 2011-03-31
CY1108701T1 (el) 2014-04-09
MXPA04001047A (es) 2005-02-17
JP2012092144A (ja) 2012-05-17
US8557579B2 (en) 2013-10-15
CA2428822A1 (en) 2003-02-20
PT1985634E (pt) 2012-02-07
US20030049252A1 (en) 2003-03-13
JP4815101B2 (ja) 2011-11-16
IL204030A (en) 2014-11-30
WO2003013603A8 (en) 2004-06-10
WO2003013603A1 (en) 2003-02-20
EP1411982B1 (en) 2008-10-15
IL204030A0 (en) 2011-08-01
IL160168A (en) 2011-02-28
NO334850B1 (no) 2014-06-16
KR100850731B1 (ko) 2008-08-06
CA2428822C (en) 2014-10-28
US20130011861A1 (en) 2013-01-10
JP2004521958A (ja) 2004-07-22
KR20040054670A (ko) 2004-06-25
EP1411982A4 (en) 2004-10-06
EP1985634B1 (en) 2011-11-02
EP1411982A1 (en) 2004-04-28
US20090304709A1 (en) 2009-12-10
TWI327070B (en) 2010-07-11
PT1411982E (pt) 2008-12-24
DK1985634T3 (da) 2012-02-20
ES2376948T3 (es) 2012-03-21

Similar Documents

Publication Publication Date Title
IL204030A0 (en) Modulators of p-selectin glycoprotein ligand 1
WO2005027831A3 (en) Modulators of p-selectin glycoprotein ligand 1
EP0966485A4 (en) MUTANT AND NON-ACTIVATING IgG2 DOMAINS AND ANTI-CD3 ANTIBODIES COMPRISING THEM
SG155205A1 (en) Interleukin-10 antibodies
HK1034040A1 (en) Apo-2 ligand-anti-her-2 antibody synergism
EP1531923B8 (en) Encapsulated active particles and methods for making and using the same
TW252151B (zh)
PL339744A1 (en) Azabenzimidazole based compounds useful in modulating action of serinic/treoninoic proteinic kinase
AU5035998A (en) Enhancement of xenograft tolerance and porcine cytokines therefor
DE69736995D1 (de) Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle
TW200513262A (en) Modulators of P-selectin glycoprotein ligand 1
IL177179A0 (en) Methods of refolding mammaliam glycosyltransferases
PL325667A1 (en) Antibodies effective against fas
DK0568379T3 (da) Sammensætninger og fremgangsmåde til befugtning af partikler
SE8900835D0 (sv) Improvement in or relating to organic compounds
SE8305444L (sv) Bakterieavvisande ytor
EP0249502A3 (en) Soluble immune suppressor factor and suppressor cells
EP1100515A4 (en) $ I (EX VIVO) TREATMENT OF ALLOGENIC AND XENOGENIC T CELLS USING gp39 ANTAGONISTS
Christensen THE NATURE OF THE MARTIAN SURFACE AS DERIVED FROM THERMOPHYSICAL PROPERTIES.
ITMI932171A1 (it) Procedimento per l'estrazione di colori naturali mediante bentonite
TW206912B (en) An artificial cultivation method of eatable mushrooms
Llanso Sponges, gorgonians and corals communities of the Havana sublittoral at the west coast of Havana Bay, I. Environmental gradient.
Szlufcik et al. Modulation of inositol 1, 4, 5-trisphosphate receptor type 1 activity by thimerosal and calcium
IT1172584B (it) Metodo per la protezione biologica degli innesti delle piante, in specie del castagno, con microorganismi antagonisti
ATA20080A (de) Verfahren und vorrichtung zum reinigen von klein- gegenstaenden, wie geschirr, glaeser, bestecke u.dgl., insbesondere aus thermolabilen werkstoffen

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190308